Across TCGA pan-cancer cohorts, CYP27A1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CYP27A1 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CYP27A1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CYP27A1 expression acts as an unfavorable survival marker.
STAD, SARC, and UCEC are the cancer types where CYP27A1 Mutation most reproducibly stratifies survival.